If President Donald Trump keeps his promise, the world’s biggest drug makers will soon get access to billions of dollars siloed overseas. And if investors and analysts are right, much of that money will go toward acquisitions. So what might pharma buy with its freed-up capital?
According to a recent investor survey by EvercoreISI, these are 2017’s most likely takeout targets.
About the Author Reprints
